{"id":"W4391100832","doi":"10.1093/eurheartj/ehad889","title":"Icosapent ethyl following acute coronary syndrome: the REDUCE-IT trial","year":2024,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Fatty Acid Research and Health","field":"Nursing","cited_by":28,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université de Montréal; Montreal Heart Institute","funders":"Daiichi Sankyo Europe; St. Jude Medical; HLS Therapeutics; Idorsia Pharmaceuticals; Assistance publique-Hôpitaux de Paris; Pfizer; Moderna; Medicines Company; Regado Biosciences; Belvoir Media Group; Amarin Pharma; Novo Nordisk; MyoKardia; AstraZeneca; Amarin Corporation; Ironwood Pharmaceuticals, Incorporated; National Institutes of Health; Regeneron Pharmaceuticals; Duke Clinical Research Institute; Eisai; Brigham and Women's Hospital; Boston VA Research Institute; Boston Scientific Corporation; Eli Lilly and Company; Cleveland Clinic; Bristol-Myers Squibb; CSL Behring; Amryt Pharma; Esperion Therapeutics; Alnylam Pharmaceuticals; Amgen; Sanofi; American Heart Association","keywords":"Medicine; Acute coronary syndrome; Internal medicine; Cardiology; Myocardial infarction","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004177713,0.0002033497,0.0002531528,0.0001818151,0.00112335,0.0008368586,0.000464834,0.00004745846,0.0007914354],"category_scores_gemma":[0.0001823391,0.0001321788,0.0004557828,0.0003231952,0.0000928231,0.0003358859,0.0001359169,0.002138339,0.002797253],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000196991,"about_ca_system_score_gemma":0.0002321489,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000007933249,"about_ca_topic_score_gemma":0.00000297627,"domain_scores_codex":[0.9959512,0.001633939,0.0004891772,0.0003122867,0.0008254032,0.0007880345],"domain_scores_gemma":[0.998777,0.0003296593,0.00006115114,0.0003347862,0.00004182877,0.0004556287],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.01123988,0.0002347422,0.0005850454,0.0001008697,0.0005798702,0.02961081,0.00290361,0.00002719405,0.01373522,0.00007101348,0.9026855,0.03822628],"study_design_scores_gemma":[0.02026743,0.006334295,0.06208657,0.001662422,0.0003031185,0.05314608,0.0009221298,0.0005274983,0.001669405,0.0004229402,0.8520151,0.0006430559],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8804793,0.004126545,0.0001087785,0.09552357,0.01307838,0.0005686456,0.000008663777,0.0001652654,0.005940798],"genre_scores_gemma":[0.9924495,0.0002835128,0.0004977873,0.002995179,0.002243527,0.000004565278,0.000005829775,0.00009493015,0.001425123],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1119702,"threshold_uncertainty_score":0.9979792,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08612836554330867,"score_gpt":0.3915233961640737,"score_spread":0.305395030620765,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}